EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series

Claudio Marasca iD, Domenico D'Amico iD, Claudia Giofrè iD, Viviana Lora iD

Journal of Clinical Medicine · 08.08.2026 · 15 (16) · 6161

DOI: 10.3390/jcm15166161 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.08.2026. Verfasst von Claudio Marasca und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Medical Department, "Antonio Cardarelli" National Hospital, 80131 Naples, Italy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Almirall S.p.A., Content Ed Net S.r.l..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Patients with a clinical diagnosis of severe psoriasis complicated by comorbidities such as cardiovascular disease, obesity, metabolic syndrome and/or with the involvement of high-impact areas constitute a clinical challenge. Tildrakizumab is a monoclonal antibody targeting the IL-23/Th17 axis with a proven record of efficacy and safety in these patients.

Methods

Here we present four cases of patients with severe psoriasis and comorbidities including cardiovascular disease (Case 1), obesity (Cases 2 and 3), metabolic syndrome (Case 3), and/or high-impact areas (Cases 2–4). Three patients (Cases 1–3) had previously received biologics but developed secondary failure or loss of efficacy; one patient was bio-naïve (Case 4).

Results

The treatment with tildrakizumab in all four patients led to a quick onset (by Week 4 in all cases) of complete and lasting (1 year in Case 1, 4 years in Case 2 and 2 years in Cases 3 and 4) remission with no adverse events reported.

Conclusions

Tildrakizumab is a valuable therapeutic option for patients with psoriasis and complex clinical situations, and in particular, in cases with obesity and difficult-to-treat lesion locations such as hands, scalp and genitals. Therapeutic success is often linked to an improvement in patients’ quality of life.

Schlagwörter

Stichwörter der Autor:innen

case seriescomorbiditieshigh-impact areasmulti-treatment failuresevere psoriasis

Autor:innen und Institutionen

  • Dermatology Unit, Medical Department, "Antonio Cardarelli" National Hospital, 80131 Naples, Italy.
  • U.O.C. Dermatology, A.O.U. "Renato Dulbecco", 88100 Catanzaro, Italy.
  • U.O.C. Dermatology, A.O. "Papardo", 98158 Messina, Italy.
  • Department of Clinical Dermatology, San Gallicano Dermatological Institute (IRCCS), 00144 Rome, Italy.

ORCID-Profile: Claudio Marasca, Domenico D'Amico, Claudia Giofrè, Viviana Lora

Förderung

  • Almirall S.p.A.
  • Content Ed Net S.r.l.

Zitieren

APA

Marasca, C., D'Amico, D., Giofrè, C., & Lora, V. (2026). Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series. Journal of Clinical Medicine, 15(16), 6161. https://doi.org/10.3390/jcm15166161

Vancouver

Marasca C, D'Amico D, Giofrè C, Lora V. Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series. Journal of Clinical Medicine. 2026;15(16):6161. doi:10.3390/jcm15166161

BibTeX
@article{Marasca2026,
  author = {Marasca, Claudio and D'Amico, Domenico and Giofrè, Claudia and Lora, Viviana},
  title = {Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6161},
  doi = {10.3390/jcm15166161}
}
Kostenlos starten →